Five Medtech Trends Reshaping the 2026 Market Landscape

An Industry at an Inflection Point

The medical technology (medtech) sector is entering an era of accelerated transformation, driven by converging forces that span global pricing dynamics, care delivery models, supply chain resilience, and clinical practice. While many of these shifts have been percolating for years, the confluence of policy changes, technological enablement, and new therapeutic paradigms is creating a distinctly different competitive environment for 2026.

This analysis, informed by Clarivate’s Medtech Trends to Watch in 2026, identifies five trends that will be instrumental in shaping the market. Each represents both a challenge and an opportunity for incumbents and innovators alike. For biotech and life sciences stakeholders, understanding these dynamics is essential to navigating a landscape where value is increasingly defined by integration, adaptability, and evidence.

The Changing Global Pricing Architecture

#### Mainland China’s Volume-Based Procurement Expansion

One of the most consequential developments for global medtech is the continued expansion of Mainland China’s volume-based procurement (VBP) program. Initially introduced to broaden patient access to high-cost devices while controlling healthcare expenditure, VBP has matured into a powerful market-structuring instrument. The latest national round introduces increasingly sophisticated anchor-pricing logic, deeper price compression, and allocation mechanisms that favor domestic manufacturers.

For multinational corporations, the implications extend far beyond China. The price benchmarks and volume expectations established through VBP are increasingly referenced by other markets, particularly across emerging economies. This creates a cascading effect on global pricing strategies and portfolio decisions.

The evidence from recent procurement rounds indicates that VBP is not simply a cost-containment measure; it is a deliberate industrial policy tool. By coupling lower device prices with preferences for local suppliers, China is accelerating the development of its domestic medtech ecosystem. For foreign companies, this means that traditional market access strategies—focused on product differentiation and premium positioning—are no longer sufficient. Instead, success depends on a nuanced understanding of Chinese policy trajectories, the willingness to engage in local partnerships, and a commitment to aligning with national health priorities.

#### Strategic Implications

For medtech leaders, the key takeaway is that VBP has shifted from a localized pricing initiative to a force that influences global pricing expectations. Companies must now consider how their portfolio, manufacturing footprint, and regulatory strategy will fare in a world where price compression in one large market can profoundly affect profitability elsewhere.

The Migration to Outpatient and Ambulatory Surgical Centers

#### Care Delivery Transformation

Another defining trend is the continued migration of surgical and interventional procedures from traditional inpatient hospital settings to outpatient environments, particularly ambulatory surgical centers (ASCs). Regulatory signals in the United States reinforce this long-term trajectory. The CMS 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Payment System Final Rule further expands the ASC Covered Procedure List and continues phasing out the inpatient-only list.

These changes are enabling higher-acuity procedures—such as cardiac ablation—to be performed in lower-cost, more patient-convenient settings when clinically appropriate. This is not an isolated U.S. phenomenon; analogous shifts are occurring across many advanced health systems where payers and providers are recalibrating site-of-care strategies to reduce cost while maintaining quality.

#### Impact on Product Development and Commercial Strategy

The move to outpatient care demands that medtech companies rethink their commercial models. Products must be designed not only for the clinical capabilities of ASCs but also for the economic realities of these settings. ASCs typically require streamlined workflows, shorter procedure times, and devices that can be used by multi-disciplinary teams. Additionally, capital equipment purchases in ASCs are highly price-sensitive, favoring technologies that offer clear value proposition and rapid return on investment.

The expansion of procedure settings also changes the competitive dynamics: a device that is successful in a hospital may not automatically succeed in an ASC, particularly if it requires significant supporting infrastructure or specialized staff.

For innovation leaders, this trend underscores the importance of developing products that are intrinsically flexible and scalable—able to deliver consistent outcomes across a variety of care environments. It also highlights the need for robust real-world evidence that demonstrates not just clinical efficacy but also operational and economic benefits in outpatient settings.

Supply Chain Resilience as a Strategic Imperative

#### Tariffs, Geopolitics, and Manufacturing Geography

A third trend reshaping medtech is the recalibration of global supply chains. Tariff exposure, geopolitical tensions, and fluctuating material costs are challenging the long-standing assumption that devices should be manufactured in low-cost, geographically concentrated hubs. Companies across the industry are now prioritizing resilience over pure cost optimization.

These pressures are prompting a diversification of sourcing strategies, a re-evaluation of manufacturing footprints, and a growing emphasis on flexible, multi-region production capabilities. Larger manufacturers—with their scale and financial resources—are increasingly using integration and technology investment (such as automation and digital tracking) to buffer against global volatility. This could create a bifurcated market in which only the largest players can afford the necessary redundancies, potentially accelerating consolidation.

#### The Competitive Advantage Rethinking

Supply chain resilience is no longer solely a back-office concern; it is becoming a source of strategic advantage. Companies that can guarantee continuity of supply, even in the face of geopolitical disruptions, are likely to earn preferential contracts and stronger customer loyalty. For smaller players, collaborations and shared manufacturing platforms may provide a viable path forward.

Additionally, ongoing variability in tariffs and trade policy demands that product portfolios be rebalanced to account for regional differences. This may lead to more localized product configurations and regulatory strategies, particularly in markets that are increasingly emphasizing self-sufficiency.

The GLP-1 Effect: A Cross-Sector Ripple

#### Metabolic Therapies Rewriting Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management and type 2 diabetes is one of the most significant healthcare trends of the decade. These therapies are not only changing the treatment landscape for metabolic disease but also reshaping patient behavior, referral patterns, and the demand for certain medical devices.

While bariatric surgery remains the most effective intervention for substantial weight loss, the availability and popularity of GLP-1 drugs have expanded the treatment spectrum. This, in turn, is affecting volume across bariatric procedures. The reference indicates that the impact is not uniform—some procedures are experiencing sharper volume pressure than others—and downstream effects are beginning to emerge in areas such as diabetes care, sleep apnea, and cardiovascular monitoring.

#### A Subtle but Broad Impact

For medtech companies, this trend requires careful attention to how evolving therapeutic pathways influence the utilization of their products. Sleep apnea devices, for example, may see demand shifts as weight loss improves the condition for some patients. Cardiovascular monitoring and diagnostic devices could experience a reduction in certain patient segments if metabolic improvements lower cardiovascular risk.

The GLP-1 effect also illustrates a broader principle: that technology market viability is intertwined with the dynamic world of pharmaceutical intervention. As pharma continues to develop therapies that alter disease trajectories, device manufacturers must continuously reassess their market projections and R&D investments in response.

The Rise of Platform-Based Competition

#### Beyond Devices: Integrated Ecosystems

Finally, enabling technologies—robotics, imaging, navigation, digital workflow software—are fundamentally reshaping how medtech companies compete. These technologies are no longer add-ons to procedures; they are becoming the backbone of integrated ecosystems that span clinical planning, surgical execution, and postoperative care.

Companies are investing heavily in platform architectures that can anchor entire service lines, strengthen customer relationships, and unlock new, data-driven value propositions. For instance, a surgical robotics platform that captures intraoperative data can provide actionable feedback to improve future procedures, creating a flywheel of increasing value for providers and manufacturers.

Emerging open-platform systems are also expanding flexibility, allowing hospitals to integrate best-of-breed components from different vendors. This, in turn, is creating new competitive dynamics: companies must now compete not just on device performance but on the openness, interoperability, and completeness of their ecosystems.

#### Strategic Implications for Innovators

For startups and established players alike, the platform shift means that developing a single innovative device is no longer sufficient. Success requires considering how that device fits into a broader digital architecture, how it interfaces with other technologies, and how it contributes to workflow efficiency. Data integration and security are becoming critical product attributes.

This trend also has profound implications for how medtech companies structure their partnerships and acquisition strategies. Combining hardware, software, and data capabilities will be essential to remaining competitive in an era where the user experience is increasingly determined by the entire ecosystem.

Clinical and Regulatory Perspective

The trends described above carry significant clinical and regulatory considerations. The shift to outpatient care demands that evidence-generation strategies include not only clinical endpoints but also patient-reported outcomes and operational metrics relevant to ASCs. Regulatory agencies are also expanding their focus on real-world evidence, which will be crucial for demonstrating value across new care settings.

In the supply chain arena, regulatory scrutiny is growing over manufacturing resilience and product traceability. Compliance with evolving international standards is becoming more complex as geopolitical dynamics lead to diverse requirements.

The GLP-1 trend does not directly implicate device regulation, but it highlights the need for rigorous post-market surveillance as the interplay between pharmacological and device interventions evolves. Finally, platform-based competition is moving toward healthcare IT and cybersecurity regulation, where integration and data protection are under increasing regulatory oversight.

Overall, the regulatory pathway for these emerging ecosystems will be a central determinant of their adoption. Companies that proactively engage with regulators to create favorable and predictable pathways for integrated platforms will have a competitive edge.

Future Outlook: Five to Fifteen Years

Looking ahead, these trends are likely to deepen and intertwine over the next decade.

China’s VBP may eventually become a model for other cost-constrained health systems, further compressing global price bands. Multinationals will need to evolve from selling products to delivering solutions and value-based partnerships, particularly in domestic innovation ecosystems with emerging technologies.

The outpatient migration will continue, with advances in minimally invasive surgical techniques and remote patient monitoring further pushing care out of acute hospitals. This will increase the demand for small-footprint devices that can be used in office-based and retail health settings, including the potential for a more consumer-oriented medtech segment.

Supply chains are likely to become regionalized rather than global, with companies running parallel manufacturing and sourcing strategies in the Americas, Europe, and Asia. Advances in additive manufacturing (3D printing) and on-demand production may eventually enable localized, personalized device fabrication at scale.

The GLP-1 impact may expand as oral formulations and next-generation incretin therapies gain ground. This could lead to further disruption across surgical and implant markets, while opening new opportunities in metabolic monitoring and companion diagnostics. Development of digital therapeutics for obesity and comorbidities is another likely area of activity.

Platform-based competition will move toward closed-loop platforms that integrate data from devices, wearables, and electronic health records to offer predictive and prescriptive intelligence. Artificial intelligence will play a central role in analyzing the vast data generated by these platforms, enabling truly personalized medical care.

In the broader biotechnology and life sciences context, these trends reflect a systemic shift toward value-based, data-driven, and patient-centric healthcare. Cross-sector partnerships between device, pharma, and digital health companies will become standard as stakeholders work to create integrated therapies that address both procedural and long-term patient outcomes.

Conclusion

The medtech market of 2026 will be defined not by any single breakthrough but by the confluence of structural forces reshaping the industry. The expansion of China’s VBP, the migration to outpatient care, supply chain pressures, the GLP-1 effect, and the rise of platform-based competition are each significant in their own right. Together, they signal a new era in which strategic agility, ecosystem thinking, and evidence-based value creation are more important than ever.

For medtech and broader life sciences organizations, the imperative is clear: to anticipate these trends, adapt business and development models accordingly, and invest in the technologies and partnerships that will drive competitiveness in a rapidly evolving landscape. Those that succeed will not only thrive commercially but also contribute to the ongoing transformation of global healthcare delivery.

---

Key Takeaways

Global pricing shifts: China’s volume-based procurement is now a global benchmark, forcing multinationals to rethink portfolio and market-access strategies.
Outpatient care expansion: The shift to ASC settings is changing device design and commercial models.
Supply chain resilience: Tariff and geopolitical pressures are making manufacturing adaptability a strategic priority.
GLP-1 ripple effects: Metabolic drugs are altering procedure volumes and adjacent device markets, requiring vigilant market forecasting.
Platform-based competition: Integrated ecosystems incorporating robotics, data, and workflow software are becoming the central battleground for competitive advantage.

SEO Keywords

medtech trends 2026, medical device industry, volume-based procurement, ambulatory surgical centers, medtech supply chain, GLP-1 and medical devices, surgical robotics, digital health platforms, healthcare innovation, medical technology market analysis

Sources

Clarivate. (2026, April 28). Medtech Trends to Watch in 2026. Retrieved from https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026